Comprehensive Analysis of CMV-specific T cells in Human Subjects Receiving a Replication-defective Human Cytomegalovirus Vaccine

Project: Other project

StatusActive
Effective start/end date8/28/188/27/20

Funding

  • Merck Sharp & Dohme Corporation: $31,102.30